AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing

Amber Tong

When AstraZeneca wagered $200 million in cash upfront to bring in Ionis’ antisense candidate for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), it was not shy about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing

Amber Tong

Sign up to read this article for free.

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Agilent reveals plans to remodel operations as annual revenue dips

As­traZeneca says its $200M cash bet on Io­n­is’ AT­TR drug is pay­ing off — with PhI­II da­ta set­ting up FDA fil­ing

Amber Tong

Sign up to read this article for free.

more like this

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ag­i­lent re­veals plans to re­mod­el op­er­a­tions as an­nu­al rev­enue dips

AstraZeneca says its $200M cash bet on Ionis’ ATTR drug is paying off — with PhIII data setting up FDA filing

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Agilent reveals plans to remodel operations as annual revenue dips